Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

ADAPT Investigator Study Group

Research output: Contribution to journal › Article › peer-review

183 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences